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BACKGROUND: Mutations in KIT are more frequent in specific melanoma subtypes, and response to KIT inhibition is likely to depend on
the identified mutation.
METHODS: A total of 32 patients with metastatic acral or mucosal melanoma were screened for mutations in KIT exons 11, 13 and 17.
RESULTS: KIT mutations were found in 38% of mucosal and in 6% of acral melanomas. Three patients were treated with imatinib and
one with sorafenib. All four patients responded to treatment, but three have since progressed within the brain.
CONCLUSIONS: The observed clinical responses support further investigation of KIT inhibitors in metastatic melanoma, selected
according to KIT mutation status.
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KIT has been identified as a of biological importance in melanoma,
and mutations (and/or amplification) appear to be largely confined
to acral and mucosal subtypes and those associated with chronic
sun damage (Curtin et al, 2006; Beadling et al, 2008; Satzger et al,
2008). Clinical experience in patients with gastrointestinal stromal
tumour (GIST) indicates that sensitivity and resistance patterns to
the KIT kinase inhibitors can be predicted from the presence and
location of specific KIT mutations (Heinrich et al, 2006). Patients
with melanomas containing activating mutations in KIT have been
reported to respond to imatinib therapy (Lutzky et al, 2008;
Quintas-Cardama et al, 2008; Satzger et al, 2010); however, it
remains uncertain whether mutations considered to be predictive
of imatinib resistance can respond to second-generation KIT
kinase inhibitors.
This report describes the frequency of KIT mutations in a
prospectively selected group of Australian melanoma patients
identified as ‘at risk’ of harbouring a KIT mutation based on
clinical subtype. Four case reports illustrating significant clinical
responses to kinase inhibitors highlight the therapeutic potential
of KIT mutation screening in advanced melanoma. However,
central nervous system (CNS) progression following systemic
responses in three patients raises an important issue pertaining to
treatment efficacy in the setting of brain metastases.
MATERIALS AND METHODS
Patient population
Patients from two melanoma centres in Australia (Peter MacCal-
lum Cancer Centre, Melbourne and Royal Prince Alfred Hospital,
Sydney) provided informed consent for KIT mutation screening if
they had history of primary acral or mucosal melanoma between
October 2006 and December 2008. Patients with metastatic
melanoma requiring treatment were considered for a phase II
clinical trial of imatinib (http://www.clinical trials.gov; NCT
identifier: 00171912). Eligibility included the identification of an
activating mutation in KIT predicted to be sensitive to imatinib,
measurable disease as assessed by RECIST (Response Evaluation
Criteria in Solid Tumours), normal organ function and an ECOG
performance status between 0 and 2. Dosing commenced at 400 or
600mg daily with an option to escalate to 600 or 800mg depending
on the response. Each participating institutional human ethics
committee had previously reviewed and approved the study.
Genotyping
Genomic DNA obtained from 32 melanoma samples (23 meta-
stases and 9 primary tumours) were tested for mutations in KIT
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s(exons 11, 13 and 17) using high-resolution melting-screen
analysis and confirmed by direct sequencing. Details of methods
have been published previously (Handolias et al, 2010).
RESULTS
A total of 32 patient samples (16 mucosal and 16 acral) were
analysed for mutations in KIT and 7 mutations were detected
(Table 1). One acral melanoma contained an exon 17 (D820Y)
mutation, representing a mutation frequency of 6% within this
subtype. Six mucosal tumours (38%) harboured a KIT mutation,
and these spanned across all exons tested. Four patients with
metastatic mucosal melanoma were treated with a kinase inhibitor,
all of whom had heterozygous mutations confirmed by direct
sequencing. Three consented to undergo a clinical trial of imatinib,
and one patient with an exon 17 (D820Y) kinase domain mutation
consented to treatment with sorafenib (off label use), because of
predicted resistance to imatinib. All four patients had radiological
and/or clinical response to therapy as described in the following
case reports and as summarised in Table 2.
Case report (1)
A 65-year-old woman with a history of anal melanoma and
resected splenic and cerebral metastases, developed a new
pulmonary lesion 3 years later. A 21 base-pair duplication in exon
11 of KIT was identified in the splenic metastasis. On the basis of
predicted sensitivity, she was commenced on a 600mg daily dose
of imatinib and a 60% reduction in the pulmonary metastasis was
observed at 12 weeks (Figure 1). After a further 3 months of
treatment, she underwent whole brain irradiation for intracranial
progression. After 1 year of continuing with imatinib, the patient
had not developed any new systemic metastases but had advanced
further within the brain and died of progressive CNS disease.
Case report (2)
A 48-year-old woman with a recurrent vulval melanoma contain-
ing a K642E mutation in exon 13 of KIT was treated with imatinib
(400mg daily dose) following loco-regional relapse 2 years after
optimal surgical management and high-dose adjuvant radio-
therapy. A significant reduction in the uptake on FDG PET was
observed in the local recurrence, and there was complete
resolution of soft tissue metastases at multiple sites after 3 weeks
(Figure 2). The patient continued to respond to therapy with a 35%
reduction in the sum of measured lesions on CT at 12 weeks
(image not shown).
Case report (3)
A 38-year-old woman with a resected labial melanoma had an
isolated clitoral recurrence after 3 years. Visceral metastases and a
Table 1 ‘At-risk’ population screening for KIT mutations
Patient
KIT
mutation
Melanoma
subtype Site
Primary/
metastasis
1 WT Acral Fifth finger Met
2 WT Acral Thumb Met
3 D820Y exon 17 Acral First toe Primary
4 WT Acral First toe Met
5 WT Acral First toe Met
6 WT Acral First toe Met
7 WT Acral First toe Met
8 WT Acral First toe Primary
9 WT Acral First toenail Met
10 WT Acral Sole of foot Met
11 WT Acral Sole of foot Primary
12 WT Acral Sole of foot Met
13 WT Acral Sole of foot Met
14 WT Acral Foot Met
15 WT Acral Heel Primary
16 WT Acral Heel Met
17 7 codon dup exon 11 Mucosal Anal Met
18 D820Y exon 17 Mucosal Anal Met
19 V559A exon 11 Mucosal Anal Met
20 D816V exon 17 Mucosal Rectum Met
21 WT Mucosal Rectum Met
22 WT Mucosal Rectum Primary
23 WT Mucosal Nasal mucosa Primary
24 WT Mucosal Ethmoid sinus Primary
25 WT Mucosal Nasal septum Met
26 WT Mucosal Vagina Met
27 WT Mucosal Cervix Primary
28 K642E exon 13 Mucosal Vulva Met
29 WT Mucosal Vulva Met
30 WT Mucosal Vulva Primary
31 WT Mucosal Vulva Met
32 L576P exon 11 Mucosal Labia Met
Abbreviations: WT¼wild type; Met¼metastasis.
Table 2 Summary of treatment response according to KIT mutation status
Patient Mutation
KIT
inhibitor % RECIST
Best
response
LDH ULN
baseline/best response
PET
response
CNS
relapse/progression
1 21bp dup exon 11 Imatinib 60 PR 1.1/0.8 Yes Yes
2 K642E exon 13 Imatinib 35 PR 1.5/1.25 Yes No
3 L576P exon 11 Imatinib 42 PD
a 12.5/1.2 NA Yes
4 D820Y exon 17 Sorafenib 27 SD 2.8/1.3 NA Yes
Abbreviations: RECIST¼response evaluation criteria in solid tumours; NA¼not available, PR¼partial response; SD¼stable disease; PD¼progressive disease; LDH¼lactate
dehydrogenase; ULN¼upper limit of the normal/reference range; PET¼positron emission tomography; CNS¼central nervous system.
aNew bladder lesion identified at first
radiological assessment, despite dramatic clinical response and clear radiological response in pre-existing lesions.
AB
Figure 1 CT chest images of pulmonary metastasis arising from anal
melanoma at baseline (A) and then at 3 months (B) showing reduction in
the size of the lesion on imatinib (Case 1).
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ssoft tissue thigh mass were diagnosed 2 years later and
unresponsive to standard chemotherapy. An L576P mutation in
exon 11 of KIT was identified in the clitorectomy specimen and
imatinib was commenced at a 400mg daily dose. The patient’s
symptoms improved dramatically within days and her LDH
decreased from 2754 to 276IUl
 1 (upper limit of reference
range¼220IUl
 1) (Figure 3). A 42% reduction in the summed
size of target lesions was seen on CT (image not shown). The
patient then progressed at all sites despite an escalation in the dose
of imatinib to 600mg and ceased treatment after 16 weeks, dying
shortly thereafter with new brain metastases.
Case report (4)
A 62-year-old woman with anal melanoma and widespread
pulmonary metastases complicated by impending respiratory
failure, had a D820Y mutation in exon 17 of KIT in her primary
tumour. She did not respond to chemotherapy and was ineligible
for imatinib on clinical trial based on predicted resistance.
Sorafenib was commenced (400mg b.i.d.), and within days, the
patient was discharged from hospital without supplemental
oxygen. Chest imaging at 4 weeks showed a 27% reduction in
the sum of target lesions (Figure 4). Treatment was then
interrupted because of gastrointestinal toxicity, and within 2
weeks, multiple brain metastases were diagnosed. Despite whole
brain radiotherapy and re-introduction of sorafenib, the patient
died from progressive CNS disease.
DISCUSSION
This case series can be seen as proof of two points of principle.
First, clinical tumour characteristics have successfully been used to
identify a subgroup of melanoma patients with a high prevalence
of therapeutically relevant KIT mutations. Second, the genetic
location of KIT mutation has successfully been used to guide
selection of the KIT inhibitor in melanoma, echoing the broader
Figure 2 CT pelvis and FDG PET/CT images at baseline (A, B) and at 1 month (C, D) after treatment of a metastatic vulval melanoma with imatinib.
Arrows indicate areas of response (Case 2).
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Figure 3 Marked LDH response within 2 weeks of commencing imatinib
in a metastatic mucosal melanoma arising from the labia (Case 3). Dashed
line indicates upper limit of the reference range.
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inhibitor therapies in GIST (Heinrich et al, 2008).
Tyrosine kinase inhibitors demonstrate variable efficacy against
KIT mutation variants in GIST. Mutations affecting the juxta-
membrane region of the receptor result in its constitutive
activation, and are particularly responsive to imatinib, whereas
kinase domain mutations often confer resistance (Heinrich et al,
2003). The therapeutic responses to imatinib in this series mirror
the clinical experience of other melanoma patients with similar
sensitising KIT mutations (Hodi et al, 2008; Lutzky et al, 2008).
The convincing clinical response observed in the patient with the
L576P mutation in exon 11 (Case 3) is interesting to note in the
context of in vitro data demonstrating reduced sensitivity to
imatinib compared with other exon 11 mutations (Antonescu et al,
2007). It is possible that in this case, high imatinib concentrations
were achievable within the tumour which resulted in the clinical
effect. The non-sustainable response to therapy could also be
explained by reduced drug levels over time as shown in
pharmacokinetic studies of GIST patients wherein imatinib levels
decrease with ongoing use because of increased drug clearance
(Judson et al, 2005). It is likely that in these less-sensitive
mutations, increased levels of imatinib or an alternative kinase
inhibitor is required. Dasatinib has since been shown to have a
selective inhibitory effect in this KIT mutation both in vitro and in
the clinic in the setting of previous imatinib therapy (Woodman
et al, 2009).
In GIST, mutations in the kinase domain of KIT are usually due
to secondary point mutations (Kitamura and Hirotab, 2004) and
can confer resistance to imatinib due to the altered conformation
of the kinase which prevents drug interaction with the ATP
binding pocket (Frost et al, 2002; Foster et al, 2004). The last case
report in this series describes the treatment response seen in a
patient with a D820Y mutation in exon 17 treated with sorafenib
based on in vitro data predicting response (Guo et al, 2007).
Sorafenib inhibits a number of kinases (Wilhelm et al, 2004) in
addition to KIT, which cannot be excluded as contributing to the
response to treatment seen in this patient.
The increased rates of CNS metastases in this series may be
explained by the limited penetration of small molecule kinase
inhibitors into the brain, as documented in other imatinib-
sensitive malignancies such as chronic myeloid leukaemia,
Philadelphia chromosome-positive acute lymphocytic leukaemia
and GIST in which relapse within the CNS has been reported
(Takayama et al, 2002; Hughes et al, 2004; Altintas et al, 2007).
This is likely to represent a significant clinical problem as the brain
is a frequent site of relapse in melanoma. However, second-
generation tyrosine kinase inhibitors such as dasatinib have shown
some promise in Philadelphia chromosome-positive leukaemia
patients with CNS involvement (Porkka et al, 2008). Furthermore,
studies have looked at modulating the distribution of drugs such as
imatinib by targeting P-glycoprotein and other drug protein
transporters (Breedveld et al, 2005).
In conclusion, this report describes the clinical responses to KIT
kinase inhibitors in melanoma patients harbouring diverse KIT
mutations and supports the utility of selecting patients for therapy
based on the identification of KIT mutations. This study did not
test for KIT amplifications, which may also represent a melanoma
subset sensitive to kinase-directed therapy. The demonstrated
responses support the clinical testing of KIT inhibitors in the
adjuvant setting in which potentially sensitive mutations in KIT
have been identified, although the observation of frequent CNS
relapse suggests that this may be a focus of ongoing research.
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